Coronary Stent System
Dr. Luca Testa from Italy presents XLIMIT Trial.
Xlimus drug-eLuting stent: a prospectIve single-arM study to asses endothelIzaTion.
180 patients, 100% enrollment completed.
Angiographic and clinical performance of the Xlimus Stent. Follow up TVR with OCT.
Xlimus stent. Best Crossing profile on the market! SAFEPAX technology.
XLIMUS DES provides fully biodegradable drug elution.
No stent flaring. No tissue prolapse. Clinically effective.
The unique XLIMUS 6-8-10 stent cell design.
Ensures even vessel wall coverage. Any different artery lesion diameter ranging from 2.25 up to 5.00mm is stented evenly.
Homogenous, clinically effective drug delivery optimizes the anti-proliferative protection of the stented lesion segment.
Homogenous deployment distribution: Surface A1 = A2 = A3
Following the nature. Stent flexibility by design.
Controlled biodegradable Sirolimus drug release for
rapid functional endothelial healing.
No signs of vessel toxicity were found. No other safety concerns were noted in animals studied for up to 90 days.
Reliable fully biodegradable Sirolimus drug release
for rapid functional endothelial healing.
The highly biocompatible PLLA (Polylactid acid) drug containing release matrix degrades smoothly and provides an optimal release kinetic profile. Within 30 days, about 70% of the anti-proliferative drug is distributed into the surrounding arterial tissue of the stent struts, ensuring a highly effective inhibition of smooth muscle cell migration and proliferation. Pharmacokinetic study result confirm sustained anti-proliferative drug efficacy up to 120 days.
|Taxus Liberte||97 µm|
|Xience V||81 µm|
Thin stent struts minimize foreign body metal volume.
Pulse Synchronous Stent Dynamics respond to coronary artery movement, with every heart beat. Natural stent flexion minimizes friction and shear stress to avoid vessel wall trauma. For a lifetime patient safety! XLIMUS reduces the inflammatory signal potential for prevention of late restenosis.
Source: Peter Smits,MD, from the COMPARE trial presentation at TCT 2009.